Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and without chronic kidney disease (CKD). Amon...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lancet Regional Health - Americas (Online) 2024-08, Vol.36, p.100814, Article 100814
Hauptverfasser:	Narasaki, Yoko, Kovesdy, Csaba P., You, Amy S., Sumida, Keiichi, Mallisetty, Yamini, Surbhi, Satya, Thomas, Fridtjof, Amin, Alpesh N., Streja, Elani, Kalantar-Zadeh, Kamyar, Rhee, Connie M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events DPP-4 inhibitors GLP-1 receptor agonists Safety SGLT2 inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!